Premium
Rationale and design for an investigation to optimize selective serotonin reuptake inhibitor treatment for pregnant women with depression
Author(s) -
Avram MJ,
Stika CS,
RasmussenTorvik LJ,
Ciolino JD,
Pinheiro E,
George AL,
Wisner KL
Publication year - 2016
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.375
Subject(s) - serotonin reuptake inhibitor , dosing , pharmacokinetics , pregnancy , depression (economics) , medicine , reuptake inhibitor , drug , pharmacology , clinical pharmacology , serotonin uptake inhibitors , serotonin , fluoxetine , biology , receptor , macroeconomics , economics , genetics
The physiological changes of pregnancy can affect the pharmacokinetics of a drug, thereby affecting its dose requirements. Because pharmacokinetic (PK) studies in pregnant women have rarely been conducted, evidence‐based dosing adjustments are seldom available. In particular, despite the fact that the use of antidepressants has become increasingly common, pregnancy‐associated PK changes of the selective serotonin reuptake inhibitors (SSRIs) are largely unknown.